Liquidia opened at $55.20, in line with its previous close of $55.21. In the last trading session, the stock traded between $54.01 and $58.74. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Liquidia is now worth
$ 1,124.78
Giving a profit of
$ 1,024.78 (1024.78%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
+$2.94 (+5.33%)
Day High
$58.74
Day Low
$54.01
Day Open
$55.20
Prev Close
$55.21
Volume
24,53,989
1W Return
22.65%
1M Return
110.14%
3M Return
-33.89%
6M Return
9.45%
1Y Return
109.33%
Market Cap ($ Mn)
5,240
PE Ratio
48.65
PB Ratio
30.88
PEG Ratio
-
ROE
-163.27%
ROCE
-28.55%
EPS (TTM)
$-2.63
1 Week
22.65%
1 Month
110.14%
3 Months
-33.89%
6 Months
9.45%
9 Months
44.76%
Needham raises Liquidia price target to $66, maintains Buy rating
Needham analyst Serge Belanger raised Liquidia's price target to $66 from $58. Maintained Buy rating following Q3 2026 results showing strong YUTREPIA sales. Revenue reached $225.3 million, beating consensus estimates by 5.05%. Net loss widened to $236.3 million due to one-time litigation settlement charge.
YesterdayWells Fargo raises Liquidia price target to $33, keeps Equal-Weight
Wells Fargo raised Liquidia's price target to $33 from $30. The firm maintained an Equal-Weight rating on the stock. Analyst Benjamin Burnett issued the updated recommendation.
29 days agoLiquidia settles with United Therapeutics for $380.7 million; shares jump
Liquidia agreed to pay $380.7 million to settle all six pending lawsuits with United Therapeutics. Shares surged nearly 40% in premarket trading following the settlement announcement. BTIG upgraded Liquidia to Buy with a $70 price target; Needham cut target to $58. Company will fund payments via existing cash and YUTREPIA sales without raising capital.
29 days agoWells Fargo downgrades Liquidia to Equal-Weight, cuts target to $30
Wells Fargo analyst Benjamin Burnett downgraded Liquidia Corporation to Equal-Weight. Price target cut significantly from $108 to $30. Rating moved from Overweight to Equal-Weight.
1mo agoRaymond James downgrades Liquidia to Outperform, cuts PT to $53
Raymond James downgraded Liquidia to Outperform from Strong Buy. Price target cut to $53 from $106 by analyst Ryan Deschner. BTIG analyst Julian Harrison separately moved rating to Neutral.
1mo agoFDA grants Fast Track to Liquidia's YUTREPIA for systemic sclerosis treatment
FDA grants Fast Track to Liquidia's YUTREPIA for Raynaud's phenomenon in systemic sclerosis. Condition affects up to 90% of systemic sclerosis patients with blood vessel spasms. Shares up 0.70% to $70.18; trading below short-term but above long-term SMAs. Average analyst price target stands at $94.29 with a Hold consensus rating. Stock shows high momentum score (97.78) but weak value score (5.57).
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Liquidia is now worth
$ 1,124.78
Giving a profit of
$ 1,024.78 (1024.78%)
Note: Past profits do not guarantee future returns.
